commercialization of companion diagnostics. In addition, Insight Genetics' CLIA-certified Insight Molecular Labs provides unique, high-value cancer testing services to oncologists and pharmaceutical companies.

A key priority in cancer care today is increasing the effectiveness of cancer treatment through a new generation of therapies that are targeted to specific genetic biomarkers. Fast, accurate and comprehensive tests – called companion diagnostics – are required to make these targeted therapies possible. These tests help clinicians pinpoint which targeted therapies may or may not work for a particular patient.

They operate at the intersection of drug development and patient care. With a high level of scientific expertise and assay development capabilities, as well as CLIA and GLP testing services, Insight Genetics spans the spectrum of discovery, testing, and commercialization of companion diagnostics. Insight is dedicated to developing new technologies and diagnostic tests that will become cutting-edge clinical products.